Biblio

Author Title [ Type

] Year

Filters: Author is Schliemann, Christoph [Clear All Filters]

Journal Article

Beneyto-Calabuig S, Merbach AKathrin, Kniffka J-A, Antes M, Szu-Tu C, Rohde C, Waclawiczek A, Stelmach P, Gräßle S, Pervan P, et al. Clonally resolved single-cell multi-omics identifies routes of cellular differentiation in acute myeloid leukemia. Cell Stem Cell. 2023.

Shumilov, ii E, Mazzeo P, Ghandili S, Künstner A, Weidemann S, Banz Y, Ströbel P, Pollak M, Kolloch L, Beltraminelli H, et al. Diagnostic management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in close interaction with therapeutic considerations. Ann Hematol. 2024.

Niederwieser D, Lang T, Krahl R, Heinicke T, Maschmeyer G, Al-Ali HKathrin, Schwind S, Jentzsch M, Cross M, Kahl C, et al. Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study. Ann Hematol. 2023.

Angenendt L, Mikesch J-H, Schliemann C. Emerging antibody-based therapies for the treatment of acute myeloid leukemia. Cancer Treat Rev. 2022;108:102409.

Enßle JC, Wolf S, Scheich S, Weber S, Kramer M, Ruhnke L, Schliemann C, Mikesch J-H, Krause S, Sauer T, et al. Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experience. Br J Cancer. 2023.

Angenendt L, Hilgefort I, Mikesch J-H, Schlüter B, Berdel WE, Lenz G, Stelljes M, Schliemann C. Magnesium levels and outcome after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. Ann Hematol. 2020.

Schliemann C, Kessler T, Berdel AF, Hemmerle T, Angenendt L, Altvater B, Rossig C, Mikesch J-H, Lenz G, Schäfers M, et al. Phase I study of F16IL2 antibody-cytokine fusion with very low-dose araC in acute myeloid leukaemia relapse after allogeneic stem cell transplantation. Br J Haematol. 2021.

Pohlmann A, Bentgens E, Schülke C, Kuron D, Reicherts C, Marx J, Angenendt L, Mikesch J-H, Lenz G, Stelljes M, et al. Pretransplant spleen volume and outcome after hematopoietic stem cell transplantation (HSCT) in patients with acute myeloid leukemia (AML). Ann Hematol. 2023.

Stelljes M, Middeke JMoritz, Bug G, Wagner-Drouet E-M, Müller LP, Schmid C, Krause SW, Bethge W, Jost E, Platzbecker U, et al. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial. Lancet Haematol. 2024.

Eckardt J-N, Röllig C, Metzeler K, Heisig P, Stasik S, Georgi J-A, Kroschinsky F, Stölzel F, Platzbecker U, Spiekermann K, et al. Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles. Commun Med (Lond). 2023;3(1):68.